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Introduction
The use of neuromuscular blocking
medications is a frequent and essential
practice in establishing a secure airway
in patients preparing for surgery or in
emergent situations such as respiratory
distress. As an anesthesia provider, it is
vital to know the mechanism of action,
expected duration, and metabolism of
these neuromuscular blocking agents
particularly succinylcholine. A potential
serious complication that may occur in
patients that have been administered
succinylcholine is prolonged
neuromuscular blockade due to the
deficiency of pseudocholinesterase, the
enzyme produced in the liver and
present in plasma that metabolizes
succinylcholine (Branch, Rafacz, &
Boudreaux, 2011). In patients with a
pseudocholinesterase deficiency,
succinylcholine is not broken down as
quickly as would be expected, which
produces a prolonged neuromuscular
block. These patients will need
continuous ventilator support postoperatively and often admission to the
intensive care unit until muscle strength
is restored (Stoelting & Hiller, 2015).
Identifying those patients at risk and
recognizing the signs of
pseudocholinesterase deficiency are key
in avoiding complications associated
with an abnormally prolonged
neuromuscular block.

Significance of Pathophysiology

Pathophysiology

Implications for Nursing Care
.
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•

•
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Pseudocholinesterase is an enzyme
produced in the liver that
metabolizes neuromuscular
blocking agents, particularly
succinylcholine and mivarcurium,
as well as some local anesthetics.
Pseudocholinesterase hydrolyzes
succinylcholine in the plasma so
quickly that only 10% of the
medications actually reaches and
acts upon the neuromuscular
junction (NMJ).
Once at the NMJ, succinylcholine
binds to acetylcholine receptor
sites causing sustained
depolarization for a relatively short
period of time in which the patient
experiences skeletal muscle
fasiculations followed by flaccid
paralysis.
Succinylcholine diffuses away from
the NMJ down its concentration
gradient at which point muscle
function will return.
Typically, an intubating dose of
succinylcholine is rapidly
hydrolyzed by
pseudocholinesterase within 9 to
13 minutes in which 90% of the
muscle strength will be restored,
however its duration of action will
be prolonged in a deficient patient
depending on the type of genetic
abnormality present.

•

•

•

Pseudocholinesterase deficiency is
caused by either a homozygous or
heterozygous abnormal genetic
variant of the enzyme itself. An
individual that is homozygous for the
atypical gene which occurs in one in
every 3,500 people, the
neuromuscular block produced by
succinylcholine will likely last four to
eight hours and this genotype is more
likely to experience apnea and the
inability to be taken off of the
ventilator post-operatively.
An individual with a heterozygous
gene which occurs one in every 480
people, will experience the effects of
succinylcholine two times longer than
an individual with a normal genotype.
There are multiple other causes that
are less significant, but may cause a
decrease in pseudocholinesterase
activity including liver disease, old
age, pregnancy, burns, malnutrition,
neoplastic disease, the use specific
mediations such as reglan, oral
contraceptives, monamine oxidase
inhibitors, and anticholinesterase
medications (Stoelting & Hiller,
2015).

•
•
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While pseudocholinesterase deficiency is not one of the most common
complications seen with general anesthesia, it can be fatal if not recognized and
treated properly.
Since we know there is a genetic link, a thorough pre-operative assessment should
be completed including family history of this condition. Sometimes asking if the
patient or a family member was admitted to the ICU or had to be on the ventilator
for longer than expected after surgery will help to reveal a pseudocholinesterase
deficiency.
The deficiency is most often found after succinylcholine has already been given
and it is discovered that the patient’s muscle function has not returned within the
expected time frame.
There is no treatment for this genetic condition, however supportive care,
particularly ventilator support, must be given until the medication has been
adequately metabolized and the patient has regained muscle strength (Stoelting &
Hiller, 2015).

Nursing anesthesia providers to know the mechanism of action and potential
adverse effects of all medications especially neuromuscular blockers in order
properly recognize and treat a pseudocholinesterase deficiency.
Always assess muscle function using train of four monitoring with a peripheral
nerve stimulator prior to an after a neuromuscular blockade is given. This will
allow for comparison and the provider can be more confident in the degree of
muscle strength recovery prior to making the decision to extubate the patient
(International Anesthesia Research Society, 2016).
Do not extubate a patient that has not experienced muscle recovery, provide full
ventilator support, and make arrangements for a ventilator set-up in the PACU
or ICU.
Avoid the use of succinylcholine unless absolutely necessary and do not give
unless the benefits outweigh the potential costs (Quyen, 2012).
PACU and ICU nurses should familiarize themselves with the significance of a
pseucholinesterase deficiency, the use of a peripheral nerve stimulator, and the
necessary care for these patients postoperatively.
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Additional Resources
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A patient with pseudocholinesterase deficiency will not experience signs or
symptoms unless he or she is administered a neuromuscular blocking agent.
The major presenting sign is prolonged skeletal muscle paralysis including the
diaphragm and intercostal muscles that are required for the patient to breath.
Apnea and a lack of movement or muscle twitches when using a peripheral nerve
stimulator will present until the medication is metabolized by the body which may
not be until hours later (Whittington, et. al, 2012).
The peripheral nerve stimulator is a method for monitoring neuromuscular
blockade in which electrodes are placed either on the facial or ulnar nerve and
stimulated using various modes to produce a muscle twitch. Train-of-four is a
commonly used mode in which four simultaneous stimuli are delivered and the
number and strength of the tissues is observed by the anesthesia provider. The
goal after using a neuromuscular blocking agent and prior to extubation is four
twitches without fade which refers to the strength of the twitch. An individual
with a pseudocholinesterase deficiency may not produce any twitches depending
the amount of time that has passed since administration and the type of genetic
variant (Nagelhout, & Plaus, 2013).
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This condition will not affect the patient’s everyday life, however it may become
a life-threatening condition if the patient must undergo general anesthesia for
surgery.
For this reason anesthesia providers should always consider using less invasive
airway options or nerve blocks, both of which would not require the
administration of neuromuscular blocking agents, like succinylcholine.
If the use of a NMB cannot be avoided and there are no absolute
contradindications, then providers must be prepared to recognize, assess and
provide support to a patient that presents with a pseucholinesterase deficiency.
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